Biotechnology company providing psychedelic therapies for people suffering from mental illness conditions like PSDT and depression Mycotopia Therapies Inc. (OTCPINK: TPIA) has entered into a psilocybin supply agreement deal Havn Life Sciences (CSE: HAVN) (OTCPINK: HAVLF).
According to the agreement, Havn Life Sciences will supply Mycotopia with naturally extracted psilocybin. Mycotopia is looking forward to build a distribution channel supply of naturally extracted psilocybe spp compounds in accordance with all federal laws and local measures applicable to researchers, companies and universities.
Establishment of this naturally extracted psilocybin will put Mycotopia at a strategic position to be among the first psychedelics companies to expand their operations across the world. This agreement also opens doors for the company to enter into other supply agreements for high-quality and naturally extracted psilocybin with other companies.
“We are honored to partner with a world-class company like Havn Life Sciences on this Psilocybin Supply Agreement. Since Havn Life Sciences will supply Mycotopia Therapies with naturally-derived psilocybin, it enables Mycotopia Therapies to get to the distribution and revenue generation phase of our business plan much faster than If we had to set up our own manufacturing facilities,” said the CEO of Mycotopia, Ben Kaplan.
